"STAAR’s fourth quarter preliminary sales reflect continued growth from EVO lenses in the U.S.1 with units up 109% year over year," said Tom Frinzi, president and CEO of Staar Surgical. "We are updating our fiscal 2023 net sales outlook to approximately $340 million which takes into consideration a restorative first quarter in China ahead of what we believe will be a strong recovery in visits by patients seeking visual freedom beginning in the second quarter. Commitments by our surgeon customers in China for fiscal 2023 EVO sales growth remain at higher levels than the fourth quarter. Our updated fiscal 2023 net sales outlook of $340 million represents ICL sales growth of approximately 25% over preliminary fiscal 2022 ICL sales of $270 million."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- This Insider Just Bought Staar Surgical (NASDAQ:STAA) Shares Worth $9.1M
- Staar Surgical price target lowered to $67 from $80 at BTIG
- Staar Surgical price target lowered to $85 from $91 at Stephens
- Cutera price target lowered to $68 from $78 at Stephens
- Staar Surgical CEO Caren Mason to retire, Thomas Frinzi to succeed
